Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8138037 | 1.00 | GSR (0.48) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL6265612 | 0.95 | GSR (0.41) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL28537926 | 0.87 | DPP7 (0.32) | GSRDPP7 | |
| SCHEMBL1404247 | 0.83 | GSR (0.61) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL20240364 | 0.83 | GSR (0.61) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL344574 | 0.83 | GSR (0.61) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL680614 | 0.81 | GSR (0.59) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Hydrochloric Acid SCHEMBL3825519 | 0.81 | GSR (0.59) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Hydrochloric Acid SCHEMBL2099474 | 0.81 | GSR (0.59) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL16194521 | 0.81 | GSR (0.59) | GSRGNAI3GNAO1GNAI1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591553-A | Diamino diketone application of piperazine compound | 上海昊海生物科技股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118108617-B | Production process of trifluoroacetyl lysine | 山东极地医药科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| US-20240269301-A1 | METHOD FOR INITIATING POLYMERIZATION OF AMINO ACID N-CARBOXYANHYDRIDES IN AQUEOUS PHASE | PEKING UNIVERSITY (CN) | 2024-08-15 | — | — | US | claimed |
| CN-118108617-A | Production process of trifluoroacetyl lysine | 山东极地医药科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-117736262-A | Preparation method of tripeptide-1 | 深圳创元生物医药科技有限公司 | 2024-03-22 | — | — | CN | claimed |
| EP-4321179-A1 | METHOD FOR INITIATING POLYMERIZATION OF AMINO ACID N-CARBOXYANHYDRIDES IN AQUEOUS PHASE | Peking University (CN) | 2024-02-14 | — | — | EP | claimed |
| CN-117106013-A | Polylysine salt and purification method thereof | 北京诺康达医药科技股份有限公司 | 2023-11-24 | — | — | CN | claimed |
| WO-2023221978-A1 | POLYLYSINE SALT, PREPARATION METHOD THEREFOR, AND PURIFICATION METHOD THEREFOR | 北京诺康达医药科技股份有限公司 | 2023-11-23 | — | — | WO | claimed |
| CN-116670120-A | Process for preparing carboxylic cyclic anhydride | 北京大学 | 2023-08-29 | — | — | CN | claimed |
| CN-116143867-A | Method for preparing GHK tripeptide and blue copper peptide without condensing agent | 上海锐康生物技术研发有限公司 | 2023-05-23 | — | — | CN | claimed |
| EP-1807467-A1 | PROCESSES FOR PREPARING GLATIRAMER | Sandoz AG (CH) | 2007-07-18 | — | — | EP | claimed |
| EP-1799703-A2 | PROCESS FOR PREPARATION OF MIXTURES OF POLYPEPTIDES USING PURIFIED HYDROBROMIC ACID | Teva Pharmaceutical Industries Ltd (IL) | 2007-06-27 | — | — | EP | claimed |
| EP-1797109-A2 | MIXTURES OF POLYPEPTIDES, COMPOSITIONS CONTAINING AND PROCESSES FOR PREPARING SAME, AND USES THEREOF | Yeda Research and Development Co. Ltd. (IL) | 2007-06-20 | — | — | EP | claimed |
| CN-1310673-C | Composition of multiple scattered mixture contg.polypeptide and its pharm compsn. | YEDA RES & DEV (IL) | 2007-04-18 | — | — | CN | claimed |
| US-20070021324-A1 | Process for preparation of mixtures of polypeptides using purified hydrobromic acid | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2007-01-25 | — | — | US | claimed |
| US-20060154862-A1 | Processes for preparing a polypeptide | SANDOZ AG (CH) | 2006-07-13 | — | — | US | claimed |
| US-20060122113-A1 | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-06-08 | — | — | US | claimed |
| WO-2006050122-A1 | PROCESSES FOR PREPARING GLATIRAMER | SANDOZ AG (CH) | 2006-05-11 | — | — | WO | claimed |
| WO-2006029411-A2 | MIXTURES OF POLYPEPTIDES, COMPOSITIONS CONTAINING AND PROCESSES FOR PREPARING SAME, AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-03-16 | — | — | WO | claimed |
| WO-2006029393-A2 | PROCESS FOR PREPARATION OF MIXTURES OF POLYPEPTIDES USING PURIFIED HYDROBROMIC ACID | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-03-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122113-A1 | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof | DNPEP, LNPEP, BCAT2 | GSR 4633/4885GNAI3 2019/4885GNAO1 3876/4885 |
| US-20240269301-A1 | METHOD FOR INITIATING POLYMERIZATION OF AMINO ACID N-CARBOXYANHYDRIDES IN AQUEOUS PHASE | DNPEP, DAO, BCAT1 | GSR 4470/4885GNAI3 3701/4885GNAO1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.